Table 2.
Mean Change from Baseline to End of Study (Standard Error) of TNSS and Individual Symptom Scores for ICX72 and Placebo Groups
| Symptom | ICX72 (N = 20) Placebo (N = 22) |
|||||
|---|---|---|---|---|---|---|
| Baseline | Change: baseline–end | % Rel change | Baseline | Change: baseline–end | % Rel change | |
| TNSS | 23.7 (2.2) | 12.4 (1.1) | 52% | 26.0 (2.2) | 7.7 (1.2) | 30% |
| Nasal congestion | 5.1 (0.5) | 2.7 (0.3) | 53% | 5.3 (0.4) | 1.4 (0.3) | 27% |
| Sinus pressure | 5.4 (0.5) | 3.3 (0.3) | 62% | 3.7 (0.4) | 1.5 (0.3) | 29% |
| Sinus pain | 4.5 (0.5) | 2.8 (0.3) | 64% | 4.8 (0.5) | 1.6 (0.3) | 33% |
| Headache | 4.9 (0.5) | 3.2 (0.4) | 65% | 4.8 (0.5) | 1.8 (0.3) | 37% |
| Sneezing | 1.6 (0.4) | 0.9 (0.2) | 53% | 2.4 (0.4) | 0.8 (0.2) | 19% |
| Rhinorrhea | 2.6 (0.5) | 0.5 (0.3) | 19% | 2.6 (0.4) | 0.6 (0.3) | 24% |
| PND | 4.7 (0.5) | 2.2 (0.4) | 47% | 5.6 (0.5) | 1.7 (0.3) | 30% |
Abbreviation: N, number of patients.
For each symptom, baseline differences between groups were not statistically different. Mean changes from baseline to end of study were significantly different between ICX72 and placebo for TNSS, nasal congestion, sinus pressure, sinus pain, and headache. Percent relative change of each symptom was larger for ICX72, compared with placebo, except rhinorrhea.